Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population

References

• EUROPA [webpage on the Internet]Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 Amending, As Regards Pharmacovigilance, Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use Text with EEA Relevance Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdfAccessed May 9, 2016
   Google Scholar
• ClassenDCPestotnikSLEvansRSBurkeJPComputerized surveillance of adverse drug events in hospital patientsJAMA199126620284728511942452
   PubMed Web of Science ®Google Scholar
• PeyriereHCassanSFloutardEAdverse drug events associated with hospital admissionAnn Pharmacother200337151112503925
   PubMed Web of Science ®Google Scholar
• HallasJHarvaldBGramLFDrug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of preventionJ Intern Med1990228283902394974
   PubMed Web of Science ®Google Scholar
• PirmohamedMJamesSMeakinSAdverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ20043297456151915231615
   PubMed Web of Science ®Google Scholar
• GholamiKZiaieSShalviriGAdverse drug reactions induced by cardiovascular drugs in outpatientsPharm Pract (Granada)200861515525170364
   PubMedGoogle Scholar
• MjörndalTBomanMDHäggSAdverse drug reactions as a cause for admissions to a department of internal medicinePharmacoepidemiol Drug Saf2002111657211998554
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyéLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE InvestigatorsN Engl J Med1992327106696771386652
   PubMed Web of Science ®Google Scholar
• HummaLMTerraSGPharmacogenetics and cardiovascular disease: impact on drug response and applications to disease managementAm J Health Syst Pharm200259131241125212116890
   PubMed Web of Science ®Google Scholar
• NagelePLiggettSBGenetic variation, β-blockers, and perioperative myocardial infarctionAnesthesiology201111561316132721918425
   PubMed Web of Science ®Google Scholar
• WuttkeHRauTHeideRIncreased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effectsClin Pharmacol Ther200272442943712386645
   PubMed Web of Science ®Google Scholar
• GoryachkinaKBurbelloABolduevaSBabakSBergmanUBertilssonLCYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarctionEur J Clin Pharmacol200864121163117318648788
   PubMed Web of Science ®Google Scholar
• ShinJJohnsonJAPharmacogenetics of beta-blockersPharmacotherapy200727687488717542770
   PubMed Web of Science ®Google Scholar
• BertilssonLDahlMLDalénPAl-ShurbajiAMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsBr J Clin Pharmacol200253211112211851634
   PubMed Web of Science ®Google Scholar
• DornGW2ndLiggettSBMechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failureMol Pharmacol200976346648019491328
   PubMed Web of Science ®Google Scholar
• AklilluEPerssonIBertilssonLJohanssonIRodriguesFIngelman-SundbergMFrequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 allelesJ Pharmacol Exp Ther199627814414468764380
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
   PubMed Web of Science ®Google Scholar
• DaiZLChenHWuXYRelationship between cytochrome P450 2C19*17 genotype distribution, platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrelZhong Xi Yi Jie He Xue Bao201210664765422704413
   PubMedGoogle Scholar
• MarezDLegrandMSabbaghNPolymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolutionPharmacogenetics1997731932029241659
   PubMedGoogle Scholar
• Ingelman-SundbergMSimSCGomezARodriguez-AntonaCInfluence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacol Ther2007116349652618001838
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: part IIClin Pharmacokinet2009481276180419902987
   PubMed Web of Science ®Google Scholar
• SakuyamaKSasakiTUjiieSFunctional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57)Drug Metab Dispos200836122460246718784265
   PubMed Web of Science ®Google Scholar
• CunninghamFAmodeMRBarrellDEnsembl 2015Nucleic Acids Res201543Database issueD662D66925352552
   PubMed Web of Science ®Google Scholar
• NaranjoCABustoUSellersEMA method for estimating the probability of adverse drug reactionsClin Pharmacol Ther19813022392457249508
   PubMed Web of Science ®Google Scholar
• EdwardsIRAronsonJKAdverse drug reactions: definitions, diagnosis, and managementLancet200035692371255125911072960
   PubMed Web of Science ®Google Scholar
• BradfordLDCYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendantsPharmacogenomics20023222924311972444
   PubMed Web of Science ®Google Scholar
• TehLKBertilssonLPharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importanceDrug Metab Pharmacokinet2012271556722185816
   PubMed Web of Science ®Google Scholar
• CYPalleles [homepage on the Internet]CYP2D6 Allele Nomenclature Available from: http://www.cypalleles.ki.seAccessed May 9, 2016
   Google Scholar
• SteenVMAndreassenOADalyAKDetection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technologyPharmacogenetics1995542152238528268
   PubMedGoogle Scholar
• NaveenATAdithanCSoyaSSGerardNKrishnamoorthyRCYP2D6 genetic polymorphism in South Indian populationsBiol Pharm Bull20062981655165816880622
   PubMed Web of Science ®Google Scholar
• JohanssonIOscarsonMYueQYBertilssonLSjöqvistFIngelman-SundbergMGenetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylationMol Pharmacol19944634524597935325
   PubMed Web of Science ®Google Scholar
• MansoorAHKaulUBeta-blockers in cardiovascular medicineJ Assoc Physicians India200957712
   Google Scholar
• LesarTSLomaestroBMPohlHMedication-prescribing errors in a teaching hospital: a nine year experienceArch Intern Med199715714156915769236558
   PubMedGoogle Scholar
• OlsenHKlemetsrudTStokkeHPTretlisSWestheimAAdverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in NorwayBlood Press1999829410110451036
   PubMed Web of Science ®Google Scholar
• HussainAAqilMAlamMSKhanMRKapurPPillaiKKA pharmacovigilance study of antihypertensive medicines at a South Delhi hospitalIndian J Pharm Sci200971333834120490310
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: part IClin Pharmacokinet2009481168972319817501
   PubMed Web of Science ®Google Scholar
• RauTHeideRBergmannKEffect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatmentPharmacogenetics200212646547212172215
   PubMedGoogle Scholar
• ZinehIBeitelsheesALGaedigkAPharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertensionClin Pharmacol Ther200476653654415592325
   PubMed Web of Science ®Google Scholar
• FuxRMörikeKPröhmerAMImpact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical studyClin Pharmacol Ther200578437838716198657
   PubMed Web of Science ®Google Scholar
• JinSKChungHJChungMWInfluence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteersJ Clin Pharm Ther200833556757318834373
   PubMed Web of Science ®Google Scholar
• BijlMJVisserLEvan SchaikRHGenetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker usersClin Pharmacol Ther2009851455018784654
   PubMed Web of Science ®Google Scholar
• RauTWuttkeHMichelsLMImpact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal studyClin Pharmacol Ther200985326927219037197
   PubMed Web of Science ®Google Scholar
• BattyJAHallASWhiteHLMERIT-HF Study GroupAn investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudyClin Pharmacol Ther201495332133024193112
   PubMed Web of Science ®Google Scholar
• SharpCFGardinerSJJensenBPCYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failurePharmacogenomics J20099317518419365402
   PubMed Web of Science ®Google Scholar
• HamadehISLangaeeTYDwivediRImpact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrateClin Pharmacol Ther201496217518124637943
   PubMed Web of Science ®Google Scholar
• AyyappadihasRDhanalekshmiUJestinHCYP 2D6*4 polymorphism and interindividual response variation to metoprolol in stage 1 hypertensive patients: no association in a rural Indian population?Turk J Med Sci201545235235726084127
   PubMed Web of Science ®Google Scholar
• SachseCBrockmöllerJBauerSRootsICytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequencesAm J Hum Genet19976022842959012401
   PubMed Web of Science ®Google Scholar
• FrommMKroemerHKEichelbaumMFImpact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugsAdv Drug Deliv Rev1997272–317119910837557
   PubMed Web of Science ®Google Scholar
• DahlMLJohanssonIBertilssonLIngelman-SundbergMSjöqvistFUltrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basisJ Pharmacol Exp Ther199527415165207616439
   PubMed Web of Science ®Google Scholar
• BertilssonLLouYQDuYLPronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoinClin Pharmacol Ther19925143883971345344
   PubMed Web of Science ®Google Scholar
• BozinaNJovanovićNLovrićMMedvedVClinical significance of a CYP2D6 poor metabolizer – a patient with schizophrenia on risperidone treatmentTher Drug Monit200830674875118806696
   PubMed Web of Science ®Google Scholar
• WestonCFPharmacogenetics and cardiovascular disease managementHosp Med2004651059459815524338
   PubMed Web of Science ®Google Scholar
• ManuntaPBianchiGPharmacogenomics and pharmacogenetics of hypertension: update and perspectives – the adducin paradigmJ Am Soc Nephrol2006174 suppl 2S30S3516565244
   PubMed Web of Science ®Google Scholar
• PereiraNLWeinshilboumRMCardiovascular pharmacogenomics and individualized drug therapyNat Rev Cardiol200961063263819707183
   PubMed Web of Science ®Google Scholar
• KangJSLeeMHOverview of therapeutic drug monitoringKorean J Intern Med200924111019270474
   PubMedGoogle Scholar